Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model

• Автори: Marianne Berdugo (Автор), Kimberley Delaunay (Автор), Cécile Lebon (Автор), Marie-Christine Naud (Автор), Lolita Radet (Автор), Léa Zennaro (Автор), Emilie Picard (Автор), Alejandra Daruich (Автор), Jacques Beltrand (Автор), Elsa Kermorvant-Duchemin (Автор), Michel Polak (Автор), Patricia Crisanti (Автор), Francine F. Behar-Cohen (Автор)
• Формат: Книга
• Опубліковано: MDPI AG, 2021-07-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Diabetic retinopathy (DR) remains a major cause of vision loss, due to macular edema, retinal ischemia and death of retinal neurons. We previously demonstrated that acute administration of glibenclamide into the vitreous, or given orally at a non-hypoglycemic dose, protected the structure and the fu...